HAYWARD, Calif. -- Impax Laboratories Inc. said Monday it is being sued by a unit of Johnson & Johnson, accused of infringing on a patent supporting the attention deficit hyperactivity drug Concerta.
Impax and its partner Teva Pharmaceutical Industries Ltd. are trying to get regulatory approval to sell low-cost versions of extended-release 54-milligram Concerta tablets. Impax said it is being sued by Johnson & Johnson’s Alza Corp. unit.
Earlier this month, Johnson & Johnson reached a deal that will allow Watson Pharmaceuticals Inc. to sell a generic version of Concerta. Watson can start selling its version on May 1. Johnson & Johnson will supply Watson with the drug and receive a share of net sales until the deal ends in 2014. Watson and J&J had been involved in a patent dispute. A court ruled that the patent at the center of the lawsuit was not valid.
After that ruling, Impax amended its filing with the FDA.
Impax said U.S. sales of Concerta 54-milligram tablets totaled $365 million over the 12 months ended Sept. 30.
Shares of Impax Labs fell 38 cents, or 2 percent, to $18.77 in afternoon trading. Teva shares rose 26 cents to $50.94 and shares of Johnson & Johnson lost 38 cents to $61.92.
Shame on these companies doing buisness by playing with lives of humans.
Gurbinder
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment